Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA CS + ME-TRAP
- Development stage
- Unknown
- Lead developer
- University of Oxford
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MVA CS + ME-TRAP is a candidate malaria vaccine that combines Modified Vaccinia Ankara (MVA) viral vector expressing two malaria antigens: Circumsporozoite protein (CS) and Multiple Epitope-Thrombospondin-Related Adhesion Protein (ME-TRAP). It is typically used in a heterologous prime-boost regimen with ChAd63 (Chimpanzee Adenovirus 63) expressing the same antigens. The vaccine is designed to induce strong T-cell responses against malaria parasites during both the sporozoite and liver stages of infection.
Beyond the preview
Go deeper on MVA CS + ME-TRAP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA CS + ME-TRAP.